Anjin small cell lung cancer treatment drug approved by FDA: can reduce tumor size and prolong lifespan
因醉鞭名马幌
发表于 2024-5-17 13:08:00
227
0
0
The US Food and Drug Administration (FDA) approved Amgen's treatment for lung cancer on Thursday (May 17).
Tarlatamab is a bispecific T cell conjugator (BiTE) antibody developed by Amgen in the United States, targeting DLL3 and CD3, as a second-line or later treatment for patients with extensive stage small cell lung cancer (ES-SCLC). The drug will be launched under the name Imdelltra.
In clinical trials, the drug has been shown to shrink tumors and significantly prolong the lifespan of small cell lung cancer patients.
Small cell lung cancer
Small cell lung cancer typically begins in the lung airways, grows rapidly, forms large tumors, and spreads throughout the body. Symptoms include phlegm with blood, cough, chest pain, and shortness of breath.
Anjin stated that among the over 2.2 million patients diagnosed with lung cancer worldwide each year, small cell lung cancer accounts for 15%, or 330000 cases. A study published in the Journal of Cancer showed that approximately 80% to 85% of small cell lung cancer patients are diagnosed with advanced lung cancer.
Dr. Jay Bradner, Chief Scientific Officer of Anjin, stated that there are approximately 35000 small cell lung cancer patients in the United States.
According to data from the American Cancer Society, only 3% of patients can survive for five years when small cell lung cancer spreads to other parts of the body; And for all patients with this disease, regardless of whether the cancer has spread or not, the five-year survival rate is 7%.
Bradner also pointed out that small cell lung cancer patients typically only have a lifespan of four to five months.
Extend lifespan
Tarlatamab is known as a bispecific T cell conjugator (BiTE), designed to redirect the immune system's T cells to recognize and kill cancer cells.
In a phase II trial based on more than 200 small cell lung cancer patients, the results showed that after taking 10 milligrams of Tarlatamab every two weeks, the cancer tumor shrank by an average of 40%.
It is worth noting that after starting to take a 10 milligram dose of Anjin medication, the median survival time of patients was 14.3 months, and 40% of patients responded to Tarlatamab treatment. By contrast, according to data from the National Cancer Institute in the United States, the average survival time of patients under current treatment methods is approximately 6 to 12 months.
Dr. Bradner from Anjin stated, "This therapy gives these patients, who typically only have a lifespan of four to five months, almost an additional year of life."
At present, Anjin Company is continuing to study several trials of Imdelltra, some of which will test the drug as an early treatment for small cell lung cancer.
Moreover, Anjin plans to launch another phase III study to use the drug as a first-line treatment for patients with advanced small cell lung cancer.
Bradner pointed out, "When you develop cancer drugs, if they work in the late stages of the disease, then when you transfer them to first-line treatment, they will play a better role."
Dr. Bradner also stated that there are currently "quite few" treatment options available for this disease, "which is one of the most terrifying cancers, so we need a new solution."
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- BeiGene Terezumab has been approved by the European Commission for the treatment of non-small cell lung cancer
- AstraZeneca: Targeted lung cancer drug Teresa? Indications for first-line combined chemotherapy for advanced non-small cell lung cancer with EGFR mutation approved in China
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏